Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trialRandomized Controlled Trial Published on 2022-11-222023-08-30 Journal: BMC Infectious Diseases [Category] E형 간염, [키워드] COVID-19 convalescent plasma COVID-19 outcomes COVID-19 therapy randomized clinical trial. [DOI] 10.1186/s12879-022-07716-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 VirusesArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Abbott Abbott SARS-CoV-2 IgG acute respiratory syndrome Analysis approach approach authorization BAU Beta binding antibody unit Canada CCP characterized Chicago Chicago IL clinical trial convalescent convalescent plasma coronavirus COVID-19 COVID-19 convalescent plasma Cutoff Delta disease course drug Emergency EUA evaluated Evidence experiment FDA food Gamma highest hospitalized patient Humoral immunity identify IgG immune IMPROVE Mann-Whitney U method comparisons Neutralization assay Neutralizing neutralizing antibody outcome Patient patient group plaque reduction neutralization plaque reduction neutralization. plasma PRNT quantitative determination required SARS-CoV-2 SARS-CoV-2 antibody selected significantly specimen tested the SARS-CoV-2 time-consuming treat United State utilization variant VLP VoC wild-type with COVID-19 [DOI] 10.1128/spectrum.02811-22 PMC 바로가기
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patientsArticle Published on 2022-10-012022-11-15 Journal: Transfusion [Category] COVID19(2023년), SARS, 진단, [키워드] 28-day mortality acute respiratory syndrome administration adverse effects adverse event adverse events antibody antibody assay Antibody Response Antibody titers Antigen assays binding case-control study CCP Characteristics characterization Control Controlled trial convalescent convalescent plasma coronavirus COVID-19 COVID-19 convalescent plasma died disease severity Donor donors enrolled evaluated group had no heterogeneous hospital Hospitalized immune response Immunosuppressed median median age Microarray NAb Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing antibody assays neutralizing capacity not affect pathogen-reduction treatment. Patient Pneumonia recipient recipients response responses SARS CoV-2 SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV2 single-center survival symptom onset transfused transfusion treated Treatment variable with COVID-19 [DOI] 10.1111/trf.17083 PMC 바로가기
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA ThresholdsArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody assay standardization assays authorization can be used CCP clinical trials Clinical use Cohort collected comparable Concordance consequence convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma criteria Cutoff cutoff value Donor drug Emergency Emergency use authorization EUA Expanded Access Program FDA FDA EUA FIVE food high-titer CCP high-titer convalescent plasma highlight hospitalized patients identification identify immunosuppressed patients indicate Limited lowest monoclonal antibody multiple serological assay Pandemics Pathogens positive precluded provided ranged reduce released Roche SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant serologic serologic assay serological Serological assay serological assays serology Serology. serum sample significantly Standardization therapeutic therapeutic option therapy threshold Treatment [DOI] 10.1128/spectrum.01154-22 PMC 바로가기
Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndromeReview article Published on 2022-08-012022-10-05 Journal: Transfusion and apheresis science : official journ [Category] SARS, 바이오마커, 임상, 치료제, [키워드] member 13 a disintegrin and metalloproteinase with a thrombospondin type 1 motif acute respiratory syndrome ADAMTS-13a disintegrin and metalloproteinase with a thrombospondin type 1 motif American Society for Apheresis approach ARDSacute respiratory syndrome article ASFAAmerican Society for Apheresis available data benefit C-reactive protein Case series Case-control CCPCOVID-19 convalescent plasma Clinical outcome Coagulopathy conducted Controlled clinical trial coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 convalescent plasma COVID-19coronavirus disease 2019 criteria Critically ill patient CRPC-reactive protein CSS CSScytokine storm syndrome Cytokine storm syndrome Cytokines D-dimer Effects Evidence excessive immune response feasibility ferritin FFPfresh frozen plasma fibrinogen level fresh frozen plasma hypercoagulable Hyperinflammatory ICUIntensive Care Unit identify IFNinterferon ILInterleukin immunomodulatory effect improvement Inflammatory factor intensive care unit interferon interleukin interleukin-6 Intervention Length of stay LOSlength of stay Lymphocyte count macrophage activation syndrome management MASmacrophage activation syndrome MODSmultiple organ dysfunction syndrome Mortality multiple organ dysfunction syndrome offer offset PaO2:FiO2pressure of arterial oxygen to fractional inspired oxygen concentration pathologic Patient patients patients with COVID-19 peer-reviewed potential clinical benefits pressure of arterial oxygen to fractional inspired oxygen concentration prevent disease progression Randomized Randomized controlled trial RCTrandomized controlled trial reduce reduce mortality resulting risk role Safe SARS-CoV-2severe acute respiratory syndrome coronavirus 2 secondary hemophagocytic lymphohistiocytosis selected Sequential Organ Failure Assessment severe acute respiratory syndrome coronavirus 2 sHLHsecondary hemophagocytic lymphohistiocytosis SOFASequential Organ Failure Assessment TAMOFthrombocytopenia-associated multiple organ failure Therapeutic plasma exchange thrombocytopenia-associated multiple organ failure TNFTumor Necrosis Factor TPE TPEtherapeutic plasma exchange treat Treatment tumor necrosis factor while with COVID-19 [DOI] 10.1016/j.transci.2022.103433 [Article Type] Review article
COVID-19 convalescent plasma: current status, lessons from the past and future perspectivesArticle Published on 2022-08-012023-07-09 Journal: Transfusion and apheresis science : official journ [Category] COVID19(2023년), [키워드] COVID-19 convalescent plasma international collaboration randomised clinical trials. [DOI] 10.1016/j.transci.2022.103487 PMC 바로가기
Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients혈청 음성 입원 환자에서 우려 일치 COVID-19 회복기 혈장 사용의 변형Article Published on 2022-06-302022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 28-day mortality advanced disease Adverse reaction Adverse reactions affecting age anti-spike monoclonal antibodies anti-spike monoclonal antibody Anti-viral therapy Blood donors CCP collected convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma Delta Efficacy hospital Hospitalized hospitalized COVID-19 patient hospitalized patient Immunocompromised Immunocompromised patient Immunocompromised patients infused IQR Italian mAb mAbs median age mortality rate NAbs Neutralizing antibodies neutralizing antibody omicron outcome patients protective immune response Randomized controlled trial recipient reported rescued SARS-CoV-2 seronegative severe COVID-19 Support Two patient two patients Usage variants variants of concern variants of concern. VoC VOCs were recorded [DOI] 10.3390/v14071443 PMC 바로가기 [Article Type] Article
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern높은 수준의 바이러스 특이적 항체가 있는 회복기 혈장은 우려되는 SARS-CoV-2 변이체를 효과적으로 중화합니다Article Published on 2022-06-282022-09-11 Journal: Blood advances [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody CCP convalescent plasma coronavirus correlated COVID-19 COVID-19 convalescent plasma Donor donors drug Drug administration effective effective drugs Efficacy Euroimmun Evolution examined exposure to food Food and Drug Administration high-titer CCP Hospitalization Immunoglobulin Immunoglobulin G Immunosuppressed limit Limited monoclonal antibody monoclonal antibody therapies neutralization neutralize neutralized plasma polyclonal reduce respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Therapies variant variants virus Virus neutralization [DOI] 10.1182/bloodadvances.2022007410 PMC 바로가기 [Article Type] Article
Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy살아있는 바이러스 중화 분석에 의한 고역가 항체 함량을 가진 COVID-19 회복기 혈장의 조기 투여는 보통의 임상 효능과 관련이 있습니다Article Published on 2022-06-012022-09-11 Journal: American journal of hematology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] absolute reduction administration administration of CCP antibody Antibody titer benefit CCP clinical benefit Clinical efficacy convalescent plasma correlation COVID-19 COVID-19 convalescent plasma Cox regression death rate death rates determined by develop Dilution Efficacy evaluate evaluated Hospitalization hospitalized patient hospitalized patients inhibitory intubated patients multivariable Cox regression neutralized Neutralizing antibody titer Non-intubated non-intubated patient non-intubated patients Patient receiving Risk factors shown stratified titer transfused Treatment two groups Viral viral neutralization viral variant Viral variants was performed with COVID-19 [DOI] 10.1002/ajh.26531 PMC 바로가기 [Article Type] Article
Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?Review Published on 2022-05-012023-07-07 Journal: Vox Sanguinis [Category] COVID19(2023년), [키워드] COVID-19 convalescent plasma SARS-CoV-2 variants of concern. [DOI] 10.1111/vox.13239 PMC 바로가기 [Article Type] Review